1. Effects of RUNX3 mediated Notch signaling pathway on biological characteristics of colorectal cancer cells.
   Hang Li et al, 2017, Int J Oncol CrossRef
2. Niclosamide: Beyond an antihelminthic drug.
   Wei Chen et al, 2018, Cell Signal CrossRef
3. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer
   Zhenbing Lv et al, 2017, J Transl Med CrossRef
4. BANCR contributes to the growth and invasion of melanoma by functioning as a competing endogenous RNA to upregulate Notch2 expression by sponging miR-204
   Bingjie Cai et al, 2017 CrossRef
5. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant
   Bei Jin et al, 2018, Cell Death Dis CrossRef
6. Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer
   Amer Alasadi et al, 2018, Cell Death Dis CrossRef
7. Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression
   Ming-Hsien Chien et al, 2018, Environmental Toxicology CrossRef
8. Cross-regulation between Notch signaling pathway and miRNA machinery in cancer
   Maryam Majidinia et al, 2018, DNA Repair CrossRef
9. Niclosamide, a Drug with Many (Re)purposes.
   Hachemi Kadri et al, 2018, ChemMedChem CrossRef
10. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer
    Abhishek Gangrade et al, 2018, IJMS CrossRef
11. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway
    Chia-Lun Wu et al, 2018, Cancer Med CrossRef
12. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo
    Dan-Dan Li et al, 2018, Cell Prolif CrossRef
13. Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells
    Jeong Yun et al, 2018, Molecules CrossRef
14. Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis
    Sara M Vliet et al, 2018 CrossRef
15. Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota
    John Tam et al, 2018, Nat Commun CrossRef
16. Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.
    N G R Dayan Elshan et al, 2019, Med Res Rev CrossRef
17. Role of mTORC1 in intestinal epithelial repair and tumorigenesis
    Harleen Kaur et al, 2019, Cell. Mol. Life Sci. CrossRef
18. Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing)
    XiuZhen Fan et al, 2019, Tuberculosis CrossRef
19. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
    Eduardo José Barbosa et al, 2019, European Journal of Pharmaceutics and Biopharmaceutics CrossRef
20. Maternal-to-zygotic transition as a potential target for niclosamide during early embryogenesis
    Sara M.F. Vliet et al, 2019, Toxicology and Applied Pharmacology CrossRef
21. MAGP2, a Component of Extracellular Matrix, Is Upregulated in Colorectal Cancer and Negatively Modulated by miR-200b-3p
    Wei Feifei et al, 2019, Technol Cancer Res Treat CrossRef
22. Repurposing of the Anti-helminthic Drug Niclosamide to Treat Melanoma and Pulmonary Metastasis via the STAT3 Signaling Pathway
    Yongxia Zhu et al, 2019, Biochemical Pharmacology CrossRef
23. NOTCH Signaling Pathway and Non-coding RNAs in Cancer
    Jing Guo et al, 2019, Pathology - Research and Practice CrossRef
24. MiR-200a acts as an oncogene in colorectal carcinoma by targeting PTEN
    Yijun Li et al, 2016, Experimental and Molecular Pathology CrossRef
25. microRNA-200a silencing protects neural stem cells against cerebral ischemia/reperfusion injury
    Ji Ma et al, 2017, PLoS ONE CrossRef
26. pH‐Responsive PEG‐Shedding and Targeting Peptide‐Modified Nanoparticles for Dual‐Delivery of Irinotecan and microRNA to Enhance Tumor‐Specific Therapy
    Vivian Juang et al, 2019, Small CrossRef
27. Hyperbranched polymer-functionalized magnetic nanoparticles mediated hyperthermia and niclosamide bimodal therapy of Colorectal Cancer Cells
    Anas Ahmad et al, 2019, ACS Biomater. Sci. Eng. CrossRef
28. The Role of Notch3 in Cancer.
    Zviadi Aburjania et al, 0 CrossRef
29. null
    David Needham, 2020 CrossRef
30. Preparation and in vitro antitumor effects on MDA-MB-231 cells of niclosamide nanocrystals stabilized by poloxamer188 and PBS
    Qiang Fu et al, 2020, International Journal of Pharmaceutics CrossRef
31. MicroRNAs alteration as early biomarkers for cancer and neurodegenerative diseases: New challenges in pesticides exposure.
    Chiara Costa et al, 2020, Toxicol Rep CrossRef
32. New drugs are not enough‑drug repositioning in oncology: An update.
    Romina Gabriela Armando et al, 2020, Int J Oncol CrossRef
33. Notch signalling pathway in development of cholangiocarcinoma
    Bisma Rauff et al, 2020, WJGO CrossRef
34. Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways
    Menna S. Zeyada et al, 2020, Life Sciences CrossRef
35. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer
    Mia M. Wu et al, 2020, Life Sciences CrossRef
36. Advancements of compounds targeting Wnt and Notch signalling pathways in the treatment of inflammatory bowel disease and colon cancer
    Zhuonan Pu et al, 2020, Journal of Drug Targeting CrossRef
37. Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma
    Gireesh B. Reddy et al, 2020, Mol Cancer Ther CrossRef
38. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer
    Atsushi Fujii et al, 2021, Cancer Sci CrossRef
39. Anthelmintics for drug repurposing: Opportunities and challenges
    Seyed Ebrahim Alavi et al, 2021, Saudi Pharmaceutical Journal CrossRef
40. Exploring the therapeutic potential of mitochondrial uncouplers in cancer
    Riya Shrestha et al, 2021, Molecular Metabolism CrossRef
41. The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways
    Manar M. Esmail et al, 2021, Toxicology Letters CrossRef
42. Identifying Novel Actionable Targets in Colon Cancer
    Maria Grazia Cerrito et al, 2021, Biomedicines CrossRef
43. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β
    Jyoti B. Kaushal et al, 2021, Cancers CrossRef
44. Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway
    Liang-Tsai Yeh et al, 2022, IJMS CrossRef
45. Niclosamide—A promising treatment for COVID‐19
    Shivani Singh et al, 2022, British J Pharmacology CrossRef
46. Loss of exosomal micro-RNA-200b-3p from hypoxia cancer-associated fibroblasts reduces sensitivity to 5-flourouracil in colorectal cancer through targeting high-mobility group box 3
    Hang Yuan et al, 2022, Front. Oncol. CrossRef
47. Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug
    Junyi Ren et al, 2022, Biomedicine & Pharmacotherapy CrossRef
48. The magic bullet: Niclosamide
    Haowen Jiang et al, 2022, Front. Oncol. CrossRef
49. Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases
    Zhan Wang et al, 2022, IJMS CrossRef
50. Mitochondrial Targeting Peptide-based Nanodelivery for Cancer Treatment
    Sumia Ehsan et al, 2022, CPPS CrossRef
51. null
    Caterina Alfano et al, 2022 CrossRef
52. Fortified anti-proliferative activity of niclosamide for breast cancer treatment: In-vitro and in-vivo assessment
    Amira Mansour et al, 2023, Life Sciences CrossRef
53. Salicylanilides and Their Anticancer Properties
    Tereza Kauerová et al, 2023, IJMS CrossRef
54. Niclosamide nanocrystal for enhanced in-vivo efficacy against gastrointestinal stromal tumor via regulating EGFR/STAT-3/DR-4 axis
    Syamprasad Np et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
55. Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
    Syue-Wei Peng et al, 2023, Cancers CrossRef
56. In Vitro and In Silico Study on the Impact of Chlorogenic Acid in Colorectal Cancer Cells: Proliferation, Apoptosis, and Interaction with β-Catenin and LRP6
    Laura Catalina Vélez-Vargas et al, 2023, Pharmaceuticals CrossRef
57. Effect of antibiotic monensin on cell proliferation and IGF1R signaling pathway in human colorectal cancer cells
    Youping Zhou et al, 2023, Annals of Medicine CrossRef
58. MUC1 aptamer-conjugated niclosamide-loaded PLGA-PEG nanoparticle attenuates HIF-1 stabilization upon hypoxia in MCF7 breast cancer cells
    Morteza Eskandani et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
59. null
    Naser-Aldin Lashgari et al, 2024 CrossRef
60. Niclosamide: A career builder PART I: (Almost) Everything You Wanted To Know About Niclosamide But Were Too Afraid To Ask PART II: Nanomedicines? A Carrier-Free Nanomedicine for Cancer and a Simple Buffered Solution to Prevent COVID19 and Other Respiratory Infections: They Just Need Testing Invited Manuscript: J Controlled Release VSI in Honor of Prof. Park
    David Needham, 2024, Journal of Controlled Release CrossRef
61. Pharmacological investigation of new niclosamide-based isatin hybrids as antiproliferative, antioxidant, and apoptosis inducers
    Mervat M. Omran et al, 2024, Sci Rep CrossRef
62. Study Deciphering the Crucial Involvement of Notch Signaling Pathway in Human Cancers
    Pratibha Pandey et al, 2024, EMIDDT CrossRef